(firstQuint)Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas.

 Because the activity of lenalidomide addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - lenalidomide is being evaluated as part of induction chemotherapy regimens for solid tumors.

 This phase II study in previously untreated metastatic pancreatic cancer is designed to establish and test the appropriate lenalidomide dose and regimen in combination with gemcitabine.

.

 Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas@highlight

To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.

